<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01538654</url>
  </required_header>
  <id_info>
    <org_study_id>EMF2011</org_study_id>
    <nct_id>NCT01538654</nct_id>
  </id_info>
  <brief_title>Enteroprotein Modified Fast ( EMF )</brief_title>
  <acronym>EMF</acronym>
  <official_title>Enteroprotein Modified Fast ( EMF ) : Clinical Safety and Efficacy. A Six Months Pilot RCT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Samir G. Sukkar</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nestl√© Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purposes of the esperience is:

        1. to verify the safety of protein sparing modified fast(PSMF) by enteral route ( EMF
           )performed in cycles of ten days/months for six months

        2. to compare EMF with oral PSMF clinically ( appetite control, fat freemass mantainance,
           polmonary function tests and metabolic pattern)

        3. to verify the weight mantainance after 6 months from the treatment suspension
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale A) primary endpoint

        1. to verify the safety of protein sparing modified fast by enteral route ( EMF )in cycles
           of ten days/months repeated for six months,

        2. To compare EMF with oral PSMF clinically ( appetite control, polmonary function tests
           and metabolic pattern) and on metabolic parameters (hypertension, glucose intolerance,
           dyslipidaemia) maintaining body composition (particularly fat free mass and muscular
           strength) in 15 patients with disease-causing obesity not responding to medical
           treatment and/or cognitive/behavioural therapy, who are candidates for invasive
           treatment such as the gastric balloon or surgery but do not intend to undergo them
           compared with 15 undergoing the same regimen without the naso-gastric tube. To verify
           the effects of treatment with regard to the enteral-hormonal structure during the acute
           phase (selected sub-group) and while undergoing treatment.

      B) Secondary endpoints:

        1. To verify the percentage of patients who maintain the weight reached 6 months after
           stopping treatment with the naso-gastric tube associated with a high-calorie
           normal-protein diet.

        2. Verify clinical safety of EN in these patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 10, 2011</start_date>
  <completion_date type="Actual">December 20, 2012</completion_date>
  <primary_completion_date type="Actual">December 20, 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>PSMF by tube feeding side effects</measure>
    <time_frame>at the day 10th /month for 6 months</time_frame>
    <description>Evaluation of side effects due to enteral nutrition by tube with a PSMF in obese subjects</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">26</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>'enteral protein tube feeding in obese</arm_group_label>
    <description>protein sparing modified fast with a defined enteral formula by tube</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>enteral protein tube feeding in obese</intervention_name>
    <description>The intervention is represented by a new alternative to treat obese patients by means of a protein sparing modified fast administered by continous 24 h enteral feeding</description>
    <arm_group_label>'enteral protein tube feeding in obese</arm_group_label>
    <other_name>EMF ( enteral modified fast )</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with BMI 30 - 45 Kg/m2
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  both genders, outpatients

          -  aged between 16 and 75

          -  with BMI 30 - 45 Kg/m2

          -  that are not in a restricted diet since at least 3 months

          -  with obesity related comorbidities (- type 2 diabetes

          -  mild or moderate OSAS

          -  orthopedic diseases (coxarthrosis, gonarthrosis)

          -  hypertension

          -  non alcoholic hepatic steatosis

          -  accepting to be enrolled in the study (signing informed consent)

        Exclusion Criteria:

          -  Presence of gastrointestinal diseases

          -  Presence of cancer

          -  Patients treated with gastrolesive or anticoagulant drugs

          -  Hepatic failure, renal failure or multi-organ failure (cut off)

          -  Contraindications for enteral nutrition,Mechanical bowel complete, or partial chronic
             obstruction

          -  Severe mesenteric ischemia not caused by hypovolemia

          -  Digiunal or ileal fistula with high output (400 mL/die)

          -  Severe modifications of the intestinal function caused by enteropathies or
             insufficient absorbent surface, to the point that a normal nutritional state cannot be
             maintained

          -  Type 1 diabetes

          -  Type 2 diabetes treated with oral or injected drugs that may cause hypoglycemia

          -  ANBN: anorexia or bulimia nervosa, evaluation of other symptoms by specific tests

          -  Patients with major psychiatric disorders or not cooperative, or with alcohol or drug
             addiction disorders.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samir G Sukkar, MD</last_name>
    <role>Study Director</role>
    <affiliation>IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2012</study_first_submitted>
  <study_first_submitted_qc>February 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2012</study_first_posted>
  <last_update_submitted>October 25, 2017</last_update_submitted>
  <last_update_submitted_qc>October 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy</investigator_affiliation>
    <investigator_full_name>M.D. Samir G. Sukkar</investigator_full_name>
    <investigator_title>Chief Clinical Nutrition Unit</investigator_title>
  </responsible_party>
  <keyword>obesity</keyword>
  <keyword>PSMF ( protein sparing modified fast)</keyword>
  <keyword>Enteral nutrition</keyword>
  <keyword>Tube feeding</keyword>
  <keyword>VLCD ( very low calorie diet)</keyword>
  <keyword>Pulmonary function tests</keyword>
  <keyword>body composition</keyword>
  <keyword>FFM ( fat free mass)</keyword>
  <keyword>Body fat</keyword>
  <keyword>Handgripstregth</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

